Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

6.42USD
25 May 2017
Change (% chg)

$-0.06 (-0.93%)
Prev Close
$6.48
Open
$6.51
Day's High
$6.57
Day's Low
$6.40
Volume
131,208
Avg. Vol
303,057
52-wk High
$7.80
52-wk Low
$4.04

KERX.OQ

Chart for KERX.OQ

About

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally... (more)

Overall

Beta: 5.20
Market Cap(Mil.): $696.36
Shares Outstanding(Mil.): 108.47
Dividend: --
Yield (%): --

Financials

  KERX.OQ Industry Sector
P/E (TTM): -- 141.29 17.43
EPS (TTM): -1.35 -- --
ROI: -108.02 2.17 -5.41
ROE: -1,065.48 0.10 -4.69

BRIEF-Keryx Biopharmaceuticals Q1 loss per share $0.21

* Keryx Biopharmaceuticals announces first quarter 2017 financial results

May 04 2017

BRIEF-Keryx says FDA accepts application to expand use of Auryxia

* Keryx biopharmaceuticals announces u.s. Fda filing acceptance of supplemental new drug application for auryxia® (ferric citrate) tablets

Mar 08 2017

BRIEF-Keryx Biopharmaceuticals reports Q4 loss per share $0.32

* Keryx Biopharmaceuticals announces fourth quarter and full year 2016 financial results

Mar 01 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €87.74 +0.43
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €83.58 +1.08
Shire PLC (SHP.L) 4,651.50 -86.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates